Biogen, Denali begin late-stage testing of Parkinson’s drug

Biogen and Denali Therapeutics said Monday that a late-stage study evaluating their experimental drug for Parkinson’s disease has started to dose patients, marking the latest milestone in a research collaboration the companies inked two years ago.